The antitumour exercise of fluoxymesterone seems linked to reduction or aggressive inhibition of prolactin receptors or estrogen receptors or manufacturing. Substitute therapy in disorders affiliated with indicators of deficiency or absence of endogenous testosterone. Description: An unhandled